FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225120168> ?p ?o ?g. }

• W4225120168 endingPage "291" @default.
• W4225120168 startingPage "282" @default.
• W4225120168 abstract "Summary Background Tofacitinib is the first in class, pan‐JAK inhibitor approved for ulcerative colitis (UC). Clinical efficacy has been shown, but long‐term real‐life endoscopic and histologic data are lacking. Aim: To investigate the effects of tofacitinib in patients with refractory UC focussing on endoscopic, histologic and molecular outcomes, including STAT3 phosphorylation (pSTAT3) detection in the spatial context of mucosal inflammation Methods We prospectively monitored 59 highly refractory patients (96.7% anti‐TNF exposure, 91.7% vedolizumab exposure) initiating tofacitinib at two IBD referral centres and assessed outcome at the end of induction and after 48 weeks of therapy. Endoscopic improvement was defined as a Mayo endoscopic subscore ≤1, endoscopic and histologic remission as Mayo endoscopic subscore 0 and Nancy histologic score 0. Multiplex immunohistochemistry with multispectral imaging was used to assess pSTAT3. Results Endoscopic improvement was achieved by 24.4% and 30.5% of patients at weeks 8 and 48, respectively. Endoscopic and histologic remission rates were 11.1%, 23.7 and 16.7%, 21.4%, respectively. Endoscopic improvement at week 8 was significantly associated with treatment continuation in the long‐term (72.7% vs 20.6%, p = 0.003). Although we observed a gradual decrease of mucosal pSTAT3 levels in both remitters and non‐remitters ( p < 0.05), no association with treatment outcome could be demonstrated. However, lamina propria pSTAT3 was significantly associated with the Nancy Histologic index ( p = 0.004). Conclusion Tofacitinib can induce and maintain endoscopic and histologic remission in up to one‐quarter of highly refractory UC patients. Longitudinal monitoring of nuclear pSTAT3 in mucosal tissue compartments reflects distinctive on‐target effects, independently of long‐term treatment outcomes." @default.
• W4225120168 created "2022-05-01" @default.
• W4225120168 creator A5003632939 @default.
• W4225120168 creator A5009144987 @default.
• W4225120168 creator A5019474609 @default.
• W4225120168 creator A5029428855 @default.
• W4225120168 creator A5034297463 @default.
• W4225120168 creator A5034994099 @default.
• W4225120168 creator A5036654221 @default.
• W4225120168 creator A5041624832 @default.
• W4225120168 creator A5049303042 @default.
• W4225120168 creator A5057185329 @default.
• W4225120168 creator A5059435501 @default.
• W4225120168 creator A5061164814 @default.
• W4225120168 creator A5067833098 @default.
• W4225120168 creator A5072584736 @default.
• W4225120168 creator A5077041880 @default.
• W4225120168 date "2022-04-28" @default.
• W4225120168 modified "2023-10-16" @default.
• W4225120168 title "Longitudinal monitoring of <scp>STAT3</scp> phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis" @default.
• W4225120168 cites W2167264906 @default.
• W4225120168 cites W2169355315 @default.
• W4225120168 cites W2334673652 @default.
• W4225120168 cites W2511494454 @default.
• W4225120168 cites W2601742683 @default.
• W4225120168 cites W2611548364 @default.
• W4225120168 cites W2912944072 @default.
• W4225120168 cites W2970926495 @default.
• W4225120168 cites W3005971833 @default.
• W4225120168 cites W3012377065 @default.
• W4225120168 cites W3014841876 @default.
• W4225120168 cites W3016092463 @default.
• W4225120168 cites W3041163404 @default.
• W4225120168 cites W3086620145 @default.
• W4225120168 cites W3088031776 @default.
• W4225120168 cites W3115410759 @default.
• W4225120168 cites W3120630781 @default.
• W4225120168 cites W3133637024 @default.
• W4225120168 cites W3135175214 @default.
• W4225120168 cites W3136576223 @default.
• W4225120168 cites W3161641132 @default.
• W4225120168 cites W3162443785 @default.
• W4225120168 doi "https://doi.org/10.1111/apt.16955" @default.
• W4225120168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35484689" @default.
• W4225120168 hasPublicationYear "2022" @default.
• W4225120168 type Work @default.
• W4225120168 citedByCount "3" @default.
• W4225120168 countsByYear W42251201682022 @default.
• W4225120168 crossrefType "journal-article" @default.
• W4225120168 hasAuthorship W4225120168A5003632939 @default.
• W4225120168 hasAuthorship W4225120168A5009144987 @default.
• W4225120168 hasAuthorship W4225120168A5019474609 @default.
• W4225120168 hasAuthorship W4225120168A5029428855 @default.
• W4225120168 hasAuthorship W4225120168A5034297463 @default.
• W4225120168 hasAuthorship W4225120168A5034994099 @default.
• W4225120168 hasAuthorship W4225120168A5036654221 @default.
• W4225120168 hasAuthorship W4225120168A5041624832 @default.
• W4225120168 hasAuthorship W4225120168A5049303042 @default.
• W4225120168 hasAuthorship W4225120168A5057185329 @default.
• W4225120168 hasAuthorship W4225120168A5059435501 @default.
• W4225120168 hasAuthorship W4225120168A5061164814 @default.
• W4225120168 hasAuthorship W4225120168A5067833098 @default.
• W4225120168 hasAuthorship W4225120168A5072584736 @default.
• W4225120168 hasAuthorship W4225120168A5077041880 @default.
• W4225120168 hasBestOaLocation W42251201682 @default.
• W4225120168 hasConcept C121332964 @default.
• W4225120168 hasConcept C126322002 @default.
• W4225120168 hasConcept C142424586 @default.
• W4225120168 hasConcept C2775862500 @default.
• W4225120168 hasConcept C2776207728 @default.
• W4225120168 hasConcept C2777575956 @default.
• W4225120168 hasConcept C2778886723 @default.
• W4225120168 hasConcept C2779134260 @default.
• W4225120168 hasConcept C2780479503 @default.
• W4225120168 hasConcept C71924100 @default.
• W4225120168 hasConcept C87355193 @default.
• W4225120168 hasConcept C90924648 @default.
• W4225120168 hasConceptScore W4225120168C121332964 @default.
• W4225120168 hasConceptScore W4225120168C126322002 @default.
• W4225120168 hasConceptScore W4225120168C142424586 @default.
• W4225120168 hasConceptScore W4225120168C2775862500 @default.
• W4225120168 hasConceptScore W4225120168C2776207728 @default.
• W4225120168 hasConceptScore W4225120168C2777575956 @default.
• W4225120168 hasConceptScore W4225120168C2778886723 @default.
• W4225120168 hasConceptScore W4225120168C2779134260 @default.
• W4225120168 hasConceptScore W4225120168C2780479503 @default.
• W4225120168 hasConceptScore W4225120168C71924100 @default.
• W4225120168 hasConceptScore W4225120168C87355193 @default.
• W4225120168 hasConceptScore W4225120168C90924648 @default.
• W4225120168 hasFunder F4320313453 @default.
• W4225120168 hasFunder F4320321730 @default.
• W4225120168 hasFunder F4320322308 @default.
• W4225120168 hasIssue "2" @default.
• W4225120168 hasLocation W42251201681 @default.
• W4225120168 hasLocation W42251201682 @default.
• W4225120168 hasLocation W42251201683 @default.
• W4225120168 hasOpenAccess W4225120168 @default.
• W4225120168 hasPrimaryLocation W42251201681 @default.

• next